Reuters logo
BRIEF-Cadila Healthcare says USFDA inspected formulations manufacturing facility at Baddi
March 2, 2017 / 8:57 AM / 7 months ago

BRIEF-Cadila Healthcare says USFDA inspected formulations manufacturing facility at Baddi

March 2 (Reuters) - Cadila Healthcare Ltd

* USFDA inspected our formulations manufacturing facility at Baddi from 20th February 2017 to 1st March 2017

* Says product is yet to be manufactured or marketed in the US

* All three observations are related to pre-approval inspection (PAI) for a specific product filed.

* Says there are no observations related to CGMP practices Source text: (bit.ly/2mO6eTl) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below